Onureg (Azacitidine)

Azacitidine, the active ingredient in Onureg, is a DNA methyltransferase inhibitor presented as a 200 mg tablet for oral use. It is indicated for maintenance therapy after achieving remission in patients with acute myeloid leukemia, helping to prolong disease‑free survival.

GNH USA supplies Onureg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable access to this oral antineoplastic agent. Our distribution network adheres to stringent quality standards and ensures timely delivery across Europe, Asia and the Americas.

Onureg (azacitidine) is used in the treatment of hematologic malignancies, specifically acute myeloid leukemia, as part of maintenance therapy. - Acute myeloid leukemia (maintenance): prolongs remission after achieving complete remission. - Acute myeloid leukemia (post‑remission): reduces risk of relapse in patients who have responded to initial therapy.

Azacitidine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Myelosuppression: reduced white blood cells, platelets, or red cells. - Fever: elevated body temperature. - Injection‑site discomfort (if oral formulation causes local irritation).

Serious or Rare Side Effects: - Severe neutropenia: heightened infection risk. - Thrombocytopenia: increased bleeding tendency. - Hepatic toxicity: abnormal liver enzymes. - Pulmonary infiltrates: breathing difficulties. - Hypersensitivity reactions: rash, swelling, or anaphylaxis. - Tumor lysis syndrome: metabolic disturbances.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess liver function: check hepatic enzymes periodically. - Evaluate infection risk: watch for signs of febrile neutropenia. - Avoid live vaccines: immunosuppression may reduce efficacy. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Azacitidine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate bone‑marrow suppression. - Live vaccines: increased risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antacids: may affect oral absorption; separate dosing by at least 2 hours. - Warfarin: monitor INR for potential bleeding changes. - CYP3A4 inducers (e.g., rifampin): may reduce azacitidine exposure. - CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Immunosuppressants (e.g., tacrolimus): monitor for additive effects.